☆ 4.7 Article

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

CLINICAL INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Christopher J. L. Murray et al.

Summary: Antimicrobial resistance (AMR) poses a significant threat to global human health, and this study provides the most comprehensive estimates of AMR burden to date. By estimating deaths and disability-adjusted life-years (DALYs) associated with bacterial AMR in 204 countries and territories in 2019, the study highlights the impact of resistance and the leading pathogen-drug combinations contributing to it.

LANCET (2022)

Add to Collection

Article Infectious Diseases

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

Patrice Nordmann et al.

Summary: The objective of this study is to characterize isolates with reduced susceptibility to cefiderocol in patients receiving cefiderocol for nosocomial pneumonia or carbapenem-resistant infections. The study found that although the minimum inhibitory concentration of some isolates increased by more than 4-fold, they remained susceptible to cefiderocol. Mutations related to enzyme activity and protein were identified in the isolates, which may contribute to the decreased susceptibility to cefiderocol.

MICROBIAL DRUG RESISTANCE (2022)

Add to Collection

Article Genetics & Heredity

Molecular Detection of blaOXA -type Carbapenemase Genes and Antimicrobial Resistance Patterns among Clinical Isolates of Acinetobacter baumannii

Maghsoud Kafshnouchi et al.

Summary: The study aimed to investigate the frequency of OXA-type carbapenemase genes among A. baumannii isolates from Hamadan hospitals, Iran, and found a high level of antibiotic resistance. The coexistence of multiple genes in A. baumannii isolates from intensive care units was associated with resistance to antibiotics.

GLOBAL MEDICAL GENETICS (2022)

Add to Collection

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Infectious Diseases

Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii

Stamatis Karakonstantis et al.

Summary: Combination antimicrobial therapy is currently the only potential treatment option for pandrug-resistant A. baumannii. Some combinations exhibit synergy at clinically relevant concentrations, with triple combinations showing greater activity than double combinations, but no combination consistently demonstrates synergy against all strains tested.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Microbiology

Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination

Noor Zaidan et al.

Summary: A successful case of treating XDR Acinetobacter baumannii pneumonia and septic shock with a novel antibiotic obtained via expanded access protocol was reported, suggesting that focused research and drug development efforts can mitigate the poor outcomes associated with these infections.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Editorial Material Microbiology

Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections

Jessica Howard-Anderson et al.

Summary: This study reports the successful treatment of carbapenem-resistant Acinetobacter baumannii infections using a novel combination therapy, showing promising results in in vitro experiments but requiring further evaluation of its clinical efficacy.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against Acinetobacter baumannii

Leilei Wang et al.

Summary: The study demonstrated that increasing the proportion of sulbactam could enhance the antimicrobial activities of three beta-lactam antibiotics combined with sulbactam against Acinetobacter baumannii clinical strains in China, with cefoperazone-sulbactam showing the highest efficacy.

INFECTION AND DRUG RESISTANCE (2021)

Add to Collection

Article Pharmacology & Pharmacy

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Sarah M. McLeod et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Microbiology

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Olexiy Sagan et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Microbiology

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

Melissa D. Barnes et al.

MBIO (2019)

Add to Collection

Article Immunology

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens

Robert A. Bonomo

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Editorial Material Infectious Diseases

A formidable foe: carbapenem-resistant Acinetobacter baumannii and emerging nonantibiotic therapies

Richard R. Watkins

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)

Add to Collection

Review Microbiology

Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges

Darren Wong et al.

CLINICAL MICROBIOLOGY REVIEWS (2017)

Add to Collection

Article Public, Environmental & Occupational Health

Failure to Communicate: Transmission of Extensively Drug-Resistant blaOXA-237-Containing Acinetobacter baumannii-Multiple Facilities in Oregon, 2012-2014

Genevieve L. Buser et al.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2017)

Add to Collection

Article Chemistry, Medicinal

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

Adam B. Shapiro et al.

ACS INFECTIOUS DISEASES (2017)

Add to Collection

Article Microbiology

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Reville et al.

NATURE MICROBIOLOGY (2017)

Add to Collection

Article Microbiology

Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam

Adam B. Shapiro

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Review Infectious Diseases

Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

E. V. Lemos et al.

CLINICAL MICROBIOLOGY AND INFECTION (2014)

Add to Collection

Article Microbiology

Early Insights into the Interactions of Different β-Lactam Antibiotics and β-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp PBP3

Krisztina M. Papp-Wallace et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)

Add to Collection

Review Infectious Diseases

Colistin in the 21st century

Roger L. Nation et al.

CURRENT OPINION IN INFECTIOUS DISEASES (2009)

Add to Collection

Review Respiratory System

Severe community-acquired Acinetobacter baumannii pneumonia: An emerging highly lethal infectious disease in the Asia-Pacific

Catherine W. M. Ong et al.

RESPIROLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.